ArticleWorld journal of urology2020
Necessity of differentiating small (< 10 mm) and large (≥ 10 mm) PI-RADS 4.
Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Comparison of MRI-guided in-bore and fusion biopsy for small PI-RADS 4 prostate lesions.World journal of urology · 2026Article
- Transperineal 3T MRI-guided and transrectal MRI-ultrasound fusion prostate biopsies: Do lesion location and size impact diagnostic yield?Urologic oncology · 2026Article
- Does Size Matter? A Retrospective Study Analysing the Size of PI-RADS 4 Lesions and Its Associated Prostate Cancer Positivity with Transperineal Prostate Biopsy.Research and reports in urology · 2025Article
- The role of the size and number of index lesion in the diagnosis of clinically significant prostate cancer in patients with PI-RADS 4 lesions who underwent in-bore MRI-guided prostate biopsy.World journal of urology · 2023Article
- Review
- New TRUS Techniques and Imaging Features of PI-RADS 4 or 5: Influence on Tumor Targeting.Frontiers in oncology · 2021Article
- Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.Journal of personalized medicine · 2020Article
- Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway.Abdominal radiology (New York) · 2020Article
- New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate Imaging Reporting and Data System version 2 (PI-RADSv2) provides reasonable performance in detecting significant cancers. Still, it is unclear about whether all PI-RADS 4 lesions show the same cancer detection rate (CDR) regardless of tumor size. The aim was to compare the CDRs of small (< 10 mm) and large (≥ 10 mm) PI-RADS 4.
methodsAfter magnetic resonance imaging (MRI) was performed in 684 men, a radiologist interpreted the MR images and detected 281 index lesions categorized as PI-RADS 4 in 281 men. PI-RADS 4 lesions were divided into small and large groups on size of 10 mm. Overall and significant CDRs were compared between the groups. A significant cancer was defined as one with Gleason score (GS) ≥ 7 or tumor volume ≥ 0.5 ml. Tumor volumes were roughly calculated as πr
resultsThe overall CDRs of small and large groups were 39.0% (53/136) and 59.3% (86/145), respectively, (p = 0.0008). The median tumor volumes of cancer-proven small and large groups were 0.18 ml (0.01-0.38 ml) and 0.70 ml (0.52-1.44 ml), respectively (p < 0.0001). Using GS or tumor volume, the significant CDRs of these groups were 26.5% (36/136) and 59.3% (86/145), respectively (p < 0.0001), and using GS alone, 26.5% (36/136) and 39.3% (57/145), respectively (p = 0.0232).
conclusionsPI-RADS 4 lesions should be sub-divided on size of 10 mm because of different significant CDRs.
Indexed as
Identifiers
31468130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.